NCT00284050View on ClinicalTrials.gov

Safety and Efficacy of Ranibizumab in Diabetic Macular Edema With Center Involvement

PHASE2CompletedINTERVENTIONAL
Enrollment

151

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
Diabetic Macular Edema
Interventions
DRUG

Ranibizumab 0.3 mg

6 mg/ml ranibizumab solution for intravitreal injection

DRUG

Ranibizumab 0.5 mg

10 mg/ml ranibizumab solution for intravitreal injection

DRUG

Sham injection

Non-treatment control for sham intravitreal injection.

Trial Locations (1)

Unknown

Novartis, Basel

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY